SutroVax is an independent vaccine platform and development company whose mission is to deliver best-in-class conjugate vaccines and novel complex antigen-based vaccines to prevent serious infectious diseases. The company is leveraging its exclusive license to Sutro Biopharma's Xpress CF platform to perform cell-free protein synthesis and site-specific conjugation for the field of vaccines.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 03/21/17 | $64,000,000 | Series B |
Abingworth CTI Life Sciences Frazier Healthcare  Longitude Capital Roche Venture Fund | undisclosed |
| 06/07/18 | $85,000,000 | Series C |
Abingworth CTI Life Sciences Foresite Capital Frazier Healthcare Longitude Capital Medicxi Roche Venture Fund TPG Growth | undisclosed |
| 03/26/20 | $110,000,000 | Series D |
Abingworth CTI Life Sciences Foresite Capital Frazier Healthcare Partners Janus Henderson Investors Longitude Capital Medixci Pivotal bioVenture Partners RA Capital Management Roche Venture Fund TPG Growth | undisclosed |
